Brief Report: First-line Pembrolizumab in Metastatic Non-Small Cell Lung Cancer Habouring MET Exon 14 Skipping Mutation and PD-L1 ≥50% (GFPC 01-20 Study) - Université Paris-Est-Créteil-Val-de-Marne
Journal Articles Clinical Lung Cancer Year : 2022

Brief Report: First-line Pembrolizumab in Metastatic Non-Small Cell Lung Cancer Habouring MET Exon 14 Skipping Mutation and PD-L1 ≥50% (GFPC 01-20 Study)

Abstract

No abstract available

Domains

Cancer
Fichier principal
Vignette du fichier
PIIS1525730422002030.pdf (498.74 Ko) Télécharger le fichier
Origin Publication funded by an institution

Claudia Tapia  : Connect in order to contact the contributor

https://hal.u-pec.fr/hal-04141332

Submitted on : Monday, June 26, 2023-11:36:18 AM

Last modification on : Tuesday, October 1, 2024-3:26:06 PM

Long-term archiving on : Wednesday, September 27, 2023-7:26:38 PM

Download

Dates and versions

hal-04141332 , version 1 (26-06-2023)

Identifiers

Cite

Florian Guisier, Renaud Descourt, Helene Babey, Eric Huchot, Lionel Falchero, et al.. Brief Report: First-line Pembrolizumab in Metastatic Non-Small Cell Lung Cancer Habouring MET Exon 14 Skipping Mutation and PD-L1 ≥50% (GFPC 01-20 Study). Clinical Lung Cancer, 2022, 23 (8), pp.e545-e549. ⟨10.1016/j.cllc.2022.09.002⟩. ⟨hal-04141332⟩

Export

BibTeX XML-TEI Dublin Core DC Terms EndNote DataCite

Collections

INSERM UNIV-ST-ETIENNE RIIP CNRS INSA-ROUEN LITIS UPEC COMUE-NORMANDIE UNIROUEN UNIV-LILLE UNILEHAVRE INSA-GROUPE UDL CANTHER
16 View
105 Download

Altmetric

Share

More